Investment analysts at Leerink Partners initiated coverage on shares of Atyr PHARMA (NASDAQ:ATYR - Get Free Report) in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage set an "outperform" rating and a $16.00 price target on the stock. Leerink Partners' target price indicates a potential upside of 270.37% from the stock's previous close.
Other analysts also recently issued reports about the company. Cantor Fitzgerald started coverage on Atyr PHARMA in a report on Monday, January 6th. They set an "overweight" rating for the company. HC Wainwright restated a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Tuesday, December 10th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Atyr PHARMA has an average rating of "Buy" and an average target price of $18.60.
Read Our Latest Analysis on Atyr PHARMA
Atyr PHARMA Trading Down 2.5 %
Shares of ATYR stock traded down $0.11 on Tuesday, reaching $4.32. 1,767,908 shares of the stock were exchanged, compared to its average volume of 987,059. The stock has a market cap of $362.62 million, a P/E ratio of -4.60 and a beta of 1.10. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a 50 day moving average of $3.61 and a two-hundred day moving average of $2.87. Atyr PHARMA has a 1-year low of $1.42 and a 1-year high of $4.66.
Institutional Trading of Atyr PHARMA
Several large investors have recently added to or reduced their stakes in ATYR. Federated Hermes Inc. acquired a new stake in Atyr PHARMA in the 4th quarter valued at $53,093,000. Point72 Asset Management L.P. acquired a new stake in Atyr PHARMA in the 4th quarter valued at $17,677,000. Tikvah Management LLC acquired a new stake in Atyr PHARMA in the 4th quarter valued at $8,908,000. Woodline Partners LP acquired a new stake in Atyr PHARMA in the 4th quarter valued at $6,092,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Atyr PHARMA in the 4th quarter valued at $4,628,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.
Atyr PHARMA Company Profile
(
Get Free Report)
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
